Isp Investments Inc.

Teva Pharmaceutical Industries Limited

Euro-celtique S.a.

Finetech Laboratories Ltd.

Finetech Pharmaceutical Ltd

Lev Yudovich

Gennady Nisnevich

Arie L Gutman

Boris Pertsikov

Boris Tishin

Igor Rukhman

Marina Etinger

Robert J Kupper

Igor Zaltzman

Irina Fedotev

Michael Yuzefovich

Ben Zion Dolitzky

Dina Blasberger

Igor Zaltsman

Anton Shalimov

Maxim Sotrihin

Alexander Vilensky

The invention provides a novel polymorphic form I of crystalline bimatoprost, method for preparation thereof and new crystalline intermediates in the preparation. This form I of crystalline bimatoprost is used in purification of crude bimatoprost and in storage of bimatoprost as active pharmaceutical intermediate. Use of the physical form of bimatoprost in the manufacture of a medicament is also disclosed.

Bimatoprost crystalline form I

The present invention provides a new and efficient process for the preparation of the dexmethylphenidate hydrochloride with high optical purity, the process comprising: The present invention further provides salt of (R,R)-N-Boc-ritalinic acid with (S)-1-phenylethylamine as new intermediate in the preparation of dexmethylphenidate hydrochloride.

Process for the preparation of dexmethylphenidate hydrochloride

The invention provides a novel process for the preparation of prostaglandins and analogues thereof, and new crystalline intermediates in the process.

Process for the preparation of prostaglandin derivatives

Methods for making thebaine and an acid salt of thebaine are disclosed herein. In one embodiment, an acid salt of thebaine is made from codeinone or an acid salt of one or more of the following: 8-methoxy-&#x394;-dihydrothebaine, codeinone dimethyl ketal, and neopinone dimethyl ketal.

Methods for making thebaine or its acid salts

The present invention relates to protected valacyclovir, N-tert-butoxycarbonyl-L-valine 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy] ethyl ester, and a method of making it. The present invention further relates to a method of making valacyclovir including the steps of coupling an amine protected valine selected from N-t-butoxycarbonyl valine and N-formyl valine with acyclovir using a coupling agent to form a protected valacyclovir, and deprotecting the protected valacyclovir to form valacyclovir or a pharmaceutically acceptable salt thereof. The present invention further relates to valacyclovir in pure form, a method of making pure valacyclovir, and to compositions containing pure valacyclovir.

Synthesis and purification of valacyclovir

Growing community of inventors

Haifa, Israel

Lev Yudovich